Seeking Alpha
 

PowerShares Dynamic Biotechnology & Genome Portfolio ETF (PBE)

- NYSEARCA
  • Dec. 30, 2014, 1:49 PM
    • In keeping with the trend of biotech focused launches in the last quarter, the ALPS Medical Breakthroughs ETF (Pending:SBIO) will be the last launch of 2014.
    • SBIO is designed to capture research and development opportunities in the biotechnology and pharmaceutical industries through small-cap and mid-cap biotechnology stocks listed in the U.S.
    • Firms with with one or more drugs in Phase II or Phase III FDA clinical trials, with a market cap between $200 million and $5 billion, will be prime candidates for investment.
    • Other domestic biotech ETFs: XBI, BBH, FBT, PBE, BBC, BBP
     
     
    | Comment!
  • Dec. 17, 2014, 10:51 AM
    • The BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) will track an index of biotechnology companies with a principal focus on running human clinical trials, while the BioShares Biotechnology Products Fund (NASDAQ:BBP) will cover biotechnology companies with one or more drugs approved by the FDA and in commercial production.
    • Both ETFs feature an equal weight index strategy, giving smaller firms a chance to make a meaningful impact on fund movements.
    • “Our BioShares funds are designed with the current biotechnology market in mind and offer investors unique and diversified portfolios of entrepreneurial biotechnology stocks by applying our rules-based index methodology,” said LifeSci Index Partners co-founder, Paul Yook in a statement.
    • Other biotech ETFs: XBI, BBH, FBT, PBE
    | Comment!
  • Oct. 31, 2014, 12:47 PM
    • The ARK Genomic Revolution Multi-Sector ETF (NYSEARCA:ARKG) is an actively managed fund that focuses on companies linked to the genomic industry across a number of sectors.
    • The ARK Innovation ETF (NYSEARCA:ARKK) will cover all three investment themes ARK now offers ETF coverage of; industrials through the ARK Industrial Innovation ETF (NYSEARCA:ARKQ), technology through the ARK Web x.0 ETF (NYSEARCA:ARKW) and genomics with ARKG.
    • "Our composite fund is a product of our approach to active management and can bring balance back to portfolios that have become increasingly benchmark-sensitive. Pulling across industries including life sciences, robotics, energy storage, social media, and cloud computing, ARKK will hold some of the most dynamic and innovative companies in the world," stated Cathie Wood, founder and CEO of ARK Investment Management, in a press release.
    • Other broad technology ETFs: IPK, IXN
    • Other biotech ETFs: XBI, BBH, FBT, PBE
    | Comment!
  • Oct. 26, 2014, 9:44 AM
    | 14 Comments
  • Jul. 8, 2014, 12:26 PM
    • Leading this week's decline are a lot of the same names which led March's "momo" selloff, among them the biotechs (XBI -4.5%) and social media (SOCL -4.4%). Also familiar, small caps (IWM -1.5%) are off more than the other major indexes.
    • Doing their jobs are the low volatility ETFs like SPLV (SPLV) and USMV (USMV -0.2%), as well as defensive sectors like the utilities (XLU +0.6%).
    • Raymond James' typically bullish Jeffrey Saut is out with a note calling for the first decent pullback of the year - a  10-12% decline - to commence later this month or early August, and he suggests investors begin raising cash.
    • Biotech ETFs: XBI, BBH, FBT, PBE
    • Low-vol ETFs: SPLV, LGLV, CFA, CFO
    • Utility ETFs: XLU, IDU, VPU, UPW, FUTY, RYU, FXU, PUI, SDP, PSCU
    | 7 Comments
  • Jun. 9, 2014, 2:53 PM
    • Those ETFs with more small- and mid-cap exposure like the SPDR S&P Biotech ETF (XBI +5.7%) and the PowerShares Dynamic Biotechnology & Genome Portfolio (PBE +7.4%) are partying. It also turns out the XBI and PBE are the two largest holders of Idenix stock.
    • Biotech ETFs with a focus on large caps - the iShares Nasdaq Biotechnology ETF (IBB +0.5%) and the Market Vectors Biotech ETF (BBH +0.4%) - are having more subdued sessions.
    • Previously: Merck buys Idenix
    • The rally in small cap biotech fueling a positive session for small caps overall, with the Russell 2000's (IWM +0.7%) gain outpacing the flat action in the big-cap averages.
    | Comment!
  • May. 13, 2014, 11:37 AM
    • General Electric (GE -0.1%) introduces SPINlab, a Carbon-13-based hyperpolarizing system that enables researchers to visualize metabolic activity at the cellular level using magnetic resonance imaging (MRI). The system simplifies MRI-based metabolic research by providing reliable access to hyperpolarized compounds in a dedicated unit.
    • The system enables the non-invasive real-time study of biochemical changes in disease processes by improving the sensitivity of MRI more than 20,000-fold.
    • Related tickers: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    | 7 Comments
  • May. 9, 2014, 9:59 AM
    • The downtrend in the biotech sector that began on February 26 ain't done yet. On a technical basis, (IBB +0.1%) has been trying to hold on to its wobbly base since its snap back move on April 15. Volume has dried up as the index struggles to stay above the key support level of the 200-day MA. This is not encouraging action for longs.
    • The relative strength line has dropped from a best-possible rating of 99 down to 68 with no upturn in sight.
    • Biotech investors should keep their powder dry until the money flow turns decidedly positive. Based on the chart, there is no indication that this is happening yet.
    • ETFs: XBI, BIB, BBH, FBT, PBE, BIS
    | 1 Comment
  • May. 8, 2014, 7:35 AM
    • China intends to end price limits on low-cost drugs after the controls caused quality problems and shortages.
    • China's economic planning body, the National Development & Reform Commission, will lift price caps on 280 drugs provided by Western companies and 250 Chinese patent medicines.
    • Sanofi (SNY) and Pfizer (PFE) said it's too early to ascertain the impact of the new policy. Other companies that could be affected include GlaxoSmithKline (GSK).
    • ETFs: IYH, IBB, XLV, XBI, VHT, BIB, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, IRY, IXJ, PPH, BIS, FHLC, PSCH, RYH, PTH, DRGS, RXD
    | Comment!
  • Apr. 25, 2014, 2:49 PM
    • Much of the high tech equipment hospitals use can be easily hacked and could pose a significant danger to patients according to the head of information security at Essentia Health.
    • Imaging equipment, insulin pumps, defibrillators and refrigerators that store blood and drugs are examples of networked gear that have remote access control features.
    • The devices' software is plagued by common security holes like weak passwords, lack of authentication to access, easy-to-determine default and hard-coded passwords and embedded web servers and administrative interfaces that make it easy to identify and manipulate devices once found on the network.
    • Hospital are apparently just waking up to the potential risks.
    • Last spring, the FDA and DHS issued a notice to the health care industry about problems with hard-coded passwords after researchers found issues in ~300 devices.
    • ETFs: IYH, IBB, XLV, XBI, VHT, BIB, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, IRY, IXJ, PPH, IHI, BIS, IHF, FHLC, XHS, PSCH, RYH, XHE, PTH, DRGS, RXD
    | Comment!
  • Apr. 25, 2014, 1:31 PM
    • Today's selloff is following the pattern of most in the past few weeks, with the small caps (IWM -1.9%) and tech (QQQ -1.5%) leading the way. Pacing declines in the Nasdaq are a 8.8% dive in Amazon post-earnings and a 4.6% fall in Facebook. Setting tongues wagging in FB - but hardly a huge deal - is the sale of another 283K shares by Sheryl Sandberg, bringing her holdings down to 8.7M shares.
    • The liquidation in biotech has previously been a convenient excuse for small cap selloffs, but the IBB is off just 1.4% today, outperforming the Russell 2000.
    • What's working? Utilities again. The XLU +0.8% today and +13% this year, outperforming the Russell 2000 by about 1.6K basis points.
    • Small cap ETFs: IWM, TZA, TNA, UWM, VB, IJR, SLY, RWJ, URTY, SCHA, TWM, RWM, SRTY, SAA, DWAS, VTWO, SDD, VIOO, JKJ, RSCO, SBB, FYX, XSLV, EWRS, TWOK, SMLV, PXSC
    • Utility ETFs: XLU, IDU, VPU, NLR, GRID, JXI, NUCL, DBU, IPU, UPW, RYU, PUI, FUTY, FXU, SDP, PSCU, UTLT
    • Biotech ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    | 7 Comments
  • Apr. 25, 2014, 12:46 PM
    • In what may be the first step in discovering how to eradicate African sleeping sickness, scientists decipher the dreaded tsetse fly's genome. The decade-long effort involved more than 149 scientists from 78 research institutions in 18 countries. It's genome contains ~12K genes and 366M letters of genetic code.
    • The fly carries the parasitic microorganism, Trypanosoma brucei, that causes Trypanosomiasis in 36 sub-Saharan countries. It transmits the pathogen in its saliva when it bites a victim. The disease is fatal if untreated.
    • The disease also afflicts cattle with a disease called Nagana.
    • The bug's biology is unusual. It gives birth to live young, it nourishes larvae inside the uterus with a milk-like substance, it finds the colors blue and black irresistible and it feeds exclusively on blood.
    • Researchers hope to identify a tsetse-specific reproductive inhibitor that has no mammalian toxicity.
    • The tsetse fly has been in mammals' ointment for at least 34M years.
    • Sleeping sickness afflicts far fewer people than malaria and dengue.
    • In 2012 there were 7,216 recorded cases according to WHO, but the incidence is most certainly under-reported.
    • ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    • ETFs: IRY, IXJ
    | Comment!
  • Apr. 22, 2014, 12:14 PM
    | Comment!
  • Apr. 22, 2014, 11:33 AM
    • The FDA proposes an "Expedited Access PMA" (EAP) process for medical devices that treat or diagnose patients with serious conditions whose medical needs are unmet by current technology. The program features earlier and more interactive participation by agency staff to collaboratively develop a plan for the collection of the scientific and clinical data to support approval. The EAP aims to reduce certain devices' development times in addition to the expected shortened premarket review.
    • Eligible devices must fit the following profile: 1) be intended to treat or diagnose a life-threatening or irreversibly-debilitating disease or condition and 2) represent one of the following: no approved alternative treatment/diagnostic exists or it represents a breakthrough technology that provides a clinically meaningful advantage over existing technology or offers a significant clinically meaningful advantage over currently-available alternatives or the device's availability is in the patient's best interest.
    • The proposed EAP builds on the Expedited Access Program for pharmaceuticals that the FDA launched in 2011.
    • Draft guidance
    • Healthcare ETFs: IYH, IBB, XLV, XBI, VHT, BIB, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, IRY, IXJ, PPH, IHI, BIS, IHF, FHLC, XHS, PSCH, RYH, XHE, PTH, DRGS, RXD
    | Comment!
  • Apr. 21, 2014, 12:56 PM
    • Three late bull market biotech IPOs are shining examples of the truism of sector rotation and the value of diving through the funding window before it closes.
    • Ultragenyx Pharmaceutical (RARE -6.4%) debuted on January 31 on robust volume of 4.4M shares. Trading opened at almost 2x the IPO price of $21 ending the day at $42.25. Prices peaked at $69.77 on March 13. Shares trade hands today at $40. The firm still sports a market cap of $1.2B despite no revenues and two products in Phase 2 clinicals.
    • Dicerna Pharmaceuticals (DRNA -1.5%) debuted on January 30 on 4M shares. Trading opened at > 2x the IPO price of $15 ending the day at $46 never to return. Today shares exchange hands at $16, a tidy 65% drop from the peak. The company has no revenues and only one product in Phase 1 clinicals.
    • Uniqure N.V. (QURE -1%) debuted on February 5 on 4.7M shares. Prices struggled to stay above the IPO price of $17 and eventually succumbed to selling pressure ending the day at $14.61. Prices peaked at $18.75 on February 26. Shares trade hands today at $8.80 representing a 53% haircut from the peak. The company has no product revenues but plans to launch its gene therapy product, Glybera, in selected European countries in H1 2014.
    • Biotech ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    | 1 Comment
  • Apr. 17, 2014, 1:30 PM
    • Scientists create patient-specific cell lines from the skin cells of two adult men in a procedure called somatic cell nuclear transfer demonstrating that the technique can work for people of all ages. The embryonic cells are genetically identical to the donor and have profound therapeutic potential.
    • The cloning procedure is difficult, however. Only one in thirty-nine attempts was successful.
    • In therapeutic cloning, a jolt of electricity fuses a grown cell (e.g. skin cell) with an ovum whose DNA has been removed. After ~5 days of dividing and multiplying it develops into a hollow sphere-shaped embryo. The interior cells are pluripotent stem cells which can develop into many different kinds of cells. The goal is to coax them to develop into specialized cells for therapeutic purposes.
    • Complicating the ability to create patient-specific cell lines for millions of people are women's reticence over donating eggs, a sometimes painful process. Widespread donations may not be ultimately necessary since many people have genetically similar immune systems so 100 human embryonic stem cell lines would match over 50% of the U.S. population according to the co-author of the study, Dr. Robert Lanza.
    • Healthcare ETFs: IYH, IBB, XLV, XBI, VHT, BIB, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, IRY, IXJ, PPH, IHI, BIS, IHF, FHLC, XHS, PSCH, RYH, PTH, XHE, DRGS, RXD
    | Comment!
PBE vs. ETF Alternatives
PBE Description
The PowerShares Dynamic Biotechnology & Genome Portfolio (Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
See more details on sponsor's website
Sector: Healthcare
Country: United States
ETF Hub
Find the right ETFs for your portfolio: Seeking Alpha's new ETF Hub